ClinicalTrials.gg
Active, not recruitingNCT06303154MOBIBRAUpdated Sep 10, 2025

Evaluation of Mobiderm Intimate Bra in the Management of Breast Edema Related to Breast Cancer Treatment

An interventional study of Mobiderm Intimate Bra group in Breast Cancer Surgery, sponsored by Thuasne. Active, not recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Thuasne · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,209 studies in Breast Neoplasms with a site in France — 207 open to participants now, 339 under way, 83 of them phase 3. Breast Neoplasms · France.

Planned enrollment
863rd of 997
30 · median 150
Started
2024
with 58 others
No phase
339 of 1,209
73 open now
Primary completion
2026-09
later than 113 of 338 live
Registered
1,073rd of 1,209
by date

Among the 1,209 studies in Breast Neoplasms with a site in France, this one is the 863rd largest by planned enrollment of the 997 interventional ones that give a count, is one of 59 that started in 2024, is one of 339 with no phase, reaches primary completion later than 113 of the 338 other live ones, and was the 1,073rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

207 of the 1,209 studies in Breast Neoplasms with a site in France are open now. Recruiting first, the newest first:

202 more — sign in →

All 207 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,209 studies in Breast Neoplasms with a site in France, or all of them as a file.
02

Study summary

The aim of this exploratory study is to assess the performance and tolerability of the MOBIDERM Intimate Bra in the management of breast edema related to breast cancer treatment.

Read the detailed description

Breast cancer is the most common malignancy in women in the Western World. BCS followed by radiotherapy is a safe and effective procedure to treat patients with early-stage [Verbelen H., 2021]. But some patients are troubled by breast edema in the operated and irradiated breast. The consequences of breast edema can be : an increase in breast volume, orange peel skin, heaviness of the breast, redness of the skin, breast pain, thickening of the skin, hyperpigmented skin pores [Verbelen H., 2014]. Breast edema can also imply deterioration in patients' quality of life, physical functioning, and body image [Young-Afat D. A., 2019].

According to the literature, only a few clinical studies evaluated the value of compression medical devices in the management of breast edema.

The aim of the study is to perform a prospective, exploratory, monocentric, uncontrolled clinical study to look at the performance and safety of Mobiderm Intimate Bra in the management of breast edema related to breast cancer treatment.

03

Conditions studied

  • Breast Cancer Surgery

Browse trials for

Keywords

  • Breast cancer
  • Surgery
  • Compressive bra
  • Breast edema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females aged 18 years and older.
  • Patients who have undergone conserving surgery for breast cancer.
  • Patients scheduled to undergo radiation treatment of the breast/chest wall within the next 12 weeks after surgery.
  • Patients with a morphology compatible with the proposed sizes of the devices, including bust girth and cup size.
  • Patients who have signed an form prior to any study intervention.
  • Patients with full legal capacity and enrolled in a social security system or covered by a similar health insurance.

Exclusion criteria

Exclusion Criteria:

  • Patients with an A cup bra size.
  • Patients with infected or acutely inflammatory skin on the chest.
  • Patients who require chemotherapy during the follow-up period.
  • Pregnant women or women of childbearing age without adequate or in the lactation period.
  • Participation in other clinical trials that impact the primary endpoint.
  • Patients with a known allergy to the device components.
  • Patients with psychiatric, psychological, or neurological disorders that are incompatible with the conduct of a clinical trial.
  • Patients unable to be followed for 12 months.
  • Vulnerable patients, or those subject to a judicial protection measure or unable to provide freely.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Mobiderm Intimate Bra group

    All the patients will wear MOBIDERM Intimate bra composed of a bra and a MOBIDERM pad

    Device: Mobiderm Intimate Bra group

Interventions

  • DeviceMobiderm Intimate Bra group

    At the conclusion of the surgical operation, MOBIDERM Intimate bra will be placed on the patient by the medical team. It will be recommended for the patients to wear MOBIDERM Intimate Bra during day and night for 3 weeks after the surgery, and as much time as the patients tolerate the device during the rest of the study, until 6 months after radiotherapy

06

What researchers measure

Primary outcomes

  1. Evolution of breast edema severity

    The evolution of breast edema severity will be assessed all along the study follow-up using the patient-completed "Symptoms" section of the Breast Edema Questionnaire (BrEQ): 8 questions about symptoms of breast edema scored on a scale from 0 to 10 (0 = no difficulty and 10: maximal difficulty). The maximum score is 80 .

    Time frame: Between 35 and 44 weeks (6 months after radiotherapy)

Secondary outcomes

  1. Comparison of methods to follow changes in the severity of breast edema - TDC measurement

    Measurement of the Tissue Dielectric Constant (TDC) of the breast tissue will be done using the MoistureMeter D (Delfin Technologies Ltd, Finland).

    Time frame: Between 35 and 44 weeks (from inclusion to 6 months after radiotherapy)

  2. Comparison of methods to follow changes in the severity of breast edema - Clinical assessment

    Clinical assessment will be done by observation and palpation of the breast by the medical team to monitor changes in the severity of breast edema.

    Time frame: Between 35 and 44 weeks (from inclusion to 6 months after radiotherapy)

  3. Comparison of methods to follow changes in the severity of breast edema - Ultrasound measurement

    High-frequency cutaneous ultrasound measurements will be done by the medical team to monitor changes in the severity of breast edema (echogenicity, skin thickness).

    Time frame: Between 35 and 44 weeks (from inclusion to 6 months after radiotherapy)

  4. Time to edema onset

    The time between surgery and/or radiotherapy and the diagnosis of breast edema will be assessed by analysing the responses to the "Symptoms" section of the BrEQ questionnaire completed weekly.

    Time frame: Between 35 and 44 weeks (from inclusion to 6 months after radiotherapy)

  5. Time to edema disappearance

    The time to disappearance of the breast edema will be assessed by analysing the responses to the "Symptoms" section of the BrEQ questionnaire completed weekly.

    Time frame: Between 35 and 44 weeks (from inclusion to 6 months after radiotherapy)

  6. Symptoms and quality of life changes associated with breast edema

    Changes in symptoms (pain, heaviness, swelling, tension, hardness and redness of the skin, etc.) and quality of life related to breast edema will be assessed by the patient by filling in the BrEQ self-questionnaire. The 8 questions related to symptoms and 16 questions related to quality of life are scored on a scale from 0 to 10 (0 = no difficulty and 10: maximal difficulty). The maximum score is 80 for the symptoms part and 160 for the Quality of life part.

    Time frame: Between 35 and 44 weeks (from inclusion to 6 months after radiotherapy)

  7. Breast edema hypersensitivity

    The evolution of breast hypersensitivity will be assessed using a Visual Analogue Scale (VAS) (score from 0 to 10 with 0 = no hypersensibility and 10 = maximum hypersensibility).

    Time frame: Between 35 and 44 weeks (from inclusion to 6 months after radiotherapy)

  8. Breast pain

    The presence of breast pain will be assessed using a VAS (score from 0 to 10 with 0 = no pain and 10 = Maximal pain).

    Time frame: Between 35 and 44 weeks (from inclusion to 6 months after radiotherapy)

  9. Skin changes associated with breast edema

    Changes in skin fibrosis/hardness will be assessed using the SkinFibroMeter (Delfin Technologies Ltd, Finland).

    Time frame: Between 35 and 44 weeks (from inclusion to 6 months after radiotherapy)

  10. Physical activity

    The time taken to resume physical activity will be measured by means of a specific question to the patient.

    Time frame: Between 35 and 44 weeks (from inclusion to 6 months after radiotherapy)

  11. Healing time

    The healing time will be calculated following observation of scar oozing by the medical team.

    Time frame: Between 35 and 44 weeks (from inclusion to 6 months after radiotherapy)

  12. Safety of the device

    The safety of the device will be assessed by describing the adverse events (AEs) and serious adverse events (SAEs) that occur throughout the study.

    Time frame: Between 35 and 44 weeks (from inclusion to 6 months after radiotherapy)

  13. Compliance to the device

    The Investigator will report compliance with the device at each visit using the patient's diary, which the patient shall complete throughout the follow-up period

    Time frame: Between 35 and 44 weeks (from inclusion to 6 months after radiotherapy)

  14. Patient's satisfaction

    Patient's satisfaction with the MOBIDERM Intimate Bra device will be evaluated with a specific self-questionnaire given to the patient.

    Time frame: 3 weeks after surgery and 6 months after radiotherapy (end of study)

07

Study locations

1 site
  • Groupe Hospitalier Paris Saint Joseph - Groupement FEHAP
    Paris, Paris 14 75014, France
08

References and documents

Publications

  • Johansson K. et al. Two-year follow-up of temporal changes of breast edema after breast cancer treatment with surgery and radiation evaluated by tissue dielectric constant (TDC). The European Journal of Lymphology and related problem. 2015; 27:73.
  • Young-Afat DA, Gregorowitsch ML, van den Bongard DH, Burgmans I, van der Pol CC, Witkamp AJ, Bijlsma RM, Koelemij R, Schoenmaeckers EJ, Jonasse Y, van Gils CH, Verkooijen HM. Breast Edema Following Breast-Conserving Surgery and Radiotherapy: Patient-Reported Prevalence, Determinants, and Effect on Health-Related Quality of Life. JNCI Cancer Spectr. 2019 Apr 16;3(2):pkz011. doi: 10.1093/jncics/pkz011. eCollection 2019 Jun. PubMed 31360894 ↗
  • Verbelen H, Gebruers N, Beyers T, De Monie AC, Tjalma W. Breast edema in breast cancer patients following breast-conserving surgery and radiotherapy: a systematic review. Breast Cancer Res Treat. 2014 Oct;147(3):463-71. doi: 10.1007/s10549-014-3110-8. Epub 2014 Aug 28. PubMed 25164973 ↗
  • Verbelen H, Tjalma W, Dombrecht D, Gebruers N. Breast edema, from diagnosis to treatment: state of the art. Arch Physiother. 2021 Mar 29;11(1):8. doi: 10.1186/s40945-021-00103-4. PubMed 33775252 ↗
  • Johansson K, Jonsson C, Bjork-Eriksson T. Compression Treatment of Breast Edema: A Randomized Controlled Pilot Study. Lymphat Res Biol. 2020 Apr;18(2):129-135. doi: 10.1089/lrb.2018.0064. Epub 2019 Jun 24. PubMed 31233373 ↗
  • Gregorowitsch ML, Van den Bongard DHJG, Batenburg MCT, Traa-van de Grootevheen MJC, Fuhler N, van Het Westeinde T, van der Pol CC, Young-Afat DA, Verkooijen HM. Compression Vest Treatment for Symptomatic Breast Edema in Women Treated for Breast Cancer: A Pilot Study. Lymphat Res Biol. 2020 Feb;18(1):56-63. doi: 10.1089/lrb.2018.0067. Epub 2019 Jun 18. PubMed 31211631 ↗
  • Verbelen H, De Vrieze T, Van Soom T, Meirte J, Van Goethem M, Hufkens G, Tjalma W, Gebruers N. Development and clinimetric properties of the Dutch Breast Edema Questionnaire (BrEQ-Dutch version) to diagnose the presence of breast edema in breast cancer patients. Qual Life Res. 2020 Feb;29(2):569-578. doi: 10.1007/s11136-019-02337-z. Epub 2019 Oct 28. PubMed 31659592 ↗
  • Mayrovitz HN, Somarriba C, Weingrad DN. Breast Tissue Dielectric Constant as a Potential Breast Edema Assessment Parameter. Lymphat Res Biol. 2022 Feb;20(1):33-38. doi: 10.1089/lrb.2020.0137. Epub 2021 Mar 24. PubMed 33761280 ↗
  • Kilbreath SL, Fearn NR, Dylke ES. Ultrasound: Assessment of breast dermal thickness: Reliability, responsiveness to change, and relationship to patient-reported outcomes. Skin Res Technol. 2022 Jan;28(1):111-118. doi: 10.1111/srt.13100. Epub 2021 Aug 29. PubMed 34455642 ↗
  • Yu Z, Liu N, Wang L, Chen J, Han L, Sun D. Assessment of Skin Properties in Chronic Lymphedema: Measurement of Skin Stiffness, Percentage Water Content, and Transepidermal Water Loss. Lymphat Res Biol. 2020 Jun;18(3):212-218. doi: 10.1089/lrb.2018.0066. Epub 2019 Oct 9. PubMed 31596657 ↗
  • Delay E, Gosset J, Toussoun G, Delaporte T, Delbaere M. [Post-treatment sequelae after breast cancer conservative surgery]. Ann Chir Plast Esthet. 2008 Apr;53(2):135-52. doi: 10.1016/j.anplas.2007.10.004. Epub 2008 Feb 20. French. PubMed 18077074 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Sep 2026, 30 months after the start.

Of 110 industry-sponsored interventional studies with no phase under Breast Neoplasms, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 59. This study's planned 30 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2024
First posted
Mar 12, 2024
StartActual
Mar 21, 2024
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06303154
Lead sponsor
Thuasne
Responsible party
Sponsor
First posted
Mar 12, 2024
Start date
Mar 21, 2024
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Sep 10, 2025

Study contacts

Séverine ALRAN, Dr
principal investigator · Groupe Hospitalier Paris Saint Joseph - Groupement FEHAP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion